CytomX Therapeutics (CTMX) Reports Break-Even Earnings for Q2

Company Performance - CytomX Therapeutics reported break-even quarterly earnings per share, surpassing the Zacks Consensus Estimate of a loss of $0.06, and improved from a loss of $0.08 per share a year ago, resulting in an earnings surprise of +100.00% [1] - The company posted revenues of $18.66 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 2.07%, although this represents a decline from year-ago revenues of $25.11 million [2] - Over the last four quarters, CytomX has consistently surpassed consensus EPS and revenue estimates [2] Stock Performance - CytomX Therapeutics shares have increased approximately 110.7% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.9% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.07 on revenues of $15.9 million, with a breakeven expectation on revenues of $98.28 million for the current fiscal year [7] - The outlook for the Medical - Biomedical and Genetics industry, where CytomX operates, is favorable, ranking in the top 41% of over 250 Zacks industries, suggesting potential for outperformance [8]